EUVIMED · CrossrefJournal
ClinicoEconomics and Outcomes Research
ISSN 1178-6981 · Informa UK Limited
Frequent topics
complicated skin and soft tissue infectionsdaptomycindirect treatment costseconomic burdenlength of hospital staylinezolidmethicillin-resistant Staphylococcus aureusoutpatient parenteral antibiotic therapyperipherally inserted central cathetervancomycin
Latest articles
Clinical and Economic Impact of Nirsevimab and Bivalent Maternal Vaccine Against RSV Infections in Infants in Italy
Economic Burden of Type 2 Diabetes Mellitus in Patient Clusters with Distinct Disease Progression Patterns: A Nationwide Study in Finland
Cost-Effectiveness Analysis of Lebrikizumab versus Dupilumab for Patients with Severe Atopic Dermatitis in Austria
Budget Impact of Adopting Office-Based Ultrasound-Guided Carpal Tunnel Release: A Commercial Claims Cost-Comparison Study
Cost-Effectiveness of Ribociclib Plus Letrozole for HR+/HER2− Advanced Breast Cancer in Thailand: A Partitioned Survival Analysis Using Real-World Evidence
What to Expect in 2026-2027: Important Health Economics and Outcomes Research Topics
Cost-Effectiveness of Fetal Fibronectin Testing in Women at Risk for Preterm Birth: A Retrospective Cohort Study
Cost-Effectiveness of Automated Blood Culture Systems: Comparison of BACT/ALERT VIRTUO and BD BACTEC FX from a Provider Perspective
Transition from Free to Paid Vaccination: Willingness to Pay for COVID-19 Booster Doses in Vietnam in the Post-Pandemic Era
Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives
Medical Claim Costs of Facioscapulohumeral Muscular Dystrophy in the United States
First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs
Cost-Effectiveness of Blinatumomab Plus Chemotherapy vs Chemotherapy in Adults Newly Diagnosed with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia in Italy
The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia
Clinical and Economic Burden Following Percutaneous Coronary Intervention for STEMI: A US Real-World Evidence Study
Economic Burden of Overall and Advanced Light Chain Amyloidosis: Results from a Claims Linked Electronic Health Record Database Analysis
Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
Model-Based Cost-Effectiveness Analysis of Routine Omega-3 Testing and Targeted Supplementation to Reduce Early Preterm Birth in Australia Compared with Current Practice
Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy
The Socioeconomic Impact of Long-Acting Injectable Buprenorphine
Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis
Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States
Research Gaps and Priorities for aHUS in the Gulf Cooperation Countries (GCC): Findings from a Payer-Focused Expert Meeting
Cancer Medication Consumptions in Vietnam Between 2019 and 2023: An Analysis from the National Database
Economic Burden of COVID-19 Hospitalization in Almaty, Kazakhstan
Real-World Treatment Patterns in Patients with Atopic Dermatitis Initiating Ruxolitinib Cream: A 12-Month Follow-Up Analysis of a US Payer Claims Database
Assessment of the Lifetime Costs of Severe Visual Impairment Due to Retinitis Pigmentosa
Healthcare Resource Utilization and the Direct Medical Cost of Fibromyalgia Patients in a Tertiary Hospital in Saudi Arabia
Cost Minimization and Cost Comparison of the Use of Conventional Double Lumen Tube versus Single-Use VivaSight-Double Lumen Tube in Thoracic Surgery: The Pascale Institute Experience
Social Impact and Economic Burden of Uncoded Hyponatremia in Elderly – A Cost-of-Illness Study
EUVIMED